Denali Therapeutics Inc. $DNLI Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 1.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,992,918 shares of the company’s stock after purchasing an additional 182,183 shares during the quarter. Vanguard Group Inc. owned about 0.08% of Denali Therapeutics worth $174,137,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Headlands Technologies LLC purchased a new position in shares of Denali Therapeutics during the 2nd quarter worth about $26,000. State of Wyoming acquired a new position in Denali Therapeutics in the second quarter valued at $29,000. PNC Financial Services Group Inc. grew its holdings in shares of Denali Therapeutics by 120.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,236 shares of the company’s stock worth $115,000 after purchasing an additional 4,494 shares during the period. MONECO Advisors LLC lifted its holdings in shares of Denali Therapeutics by 19.1% during the 3rd quarter. MONECO Advisors LLC now owns 12,478 shares of the company’s stock valued at $181,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Denali Therapeutics by 7.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company’s stock valued at $189,000 after buying an additional 930 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Trading Down 0.8%

NASDAQ:DNLI opened at $21.00 on Tuesday. The stock has a fifty day simple moving average of $19.16 and a 200 day simple moving average of $17.17. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of -7.07 and a beta of 1.02. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $23.77. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the previous year, the business earned ($0.67) EPS. Sell-side analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the sale, the insider owned 282,828 shares in the company, valued at $4,666,662. This represents a 5.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares in the company, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on DNLI shares. UBS Group began coverage on Denali Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. JPMorgan Chase & Co. raised their target price on Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $37.00 price target on Denali Therapeutics in a report on Monday, November 17th. Finally, Wedbush cut their target price on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $32.45.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.